{"schema_version":"secwatch.filing_event.v1","accession":"0000320017-25-000039","form_type":"8-K","ticker":"LSTA","cik":"0000320017","company_name":"LISATA THERAPEUTICS, INC.","filed_at":"2025-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.932306+00:00","generated_at":"2026-05-19T05:22:05.035991+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Lisata extends cash runway from Q3 2026 to Q4 2026","bullets":["Company now expects current cash to fund operations into Q4 2026, versus prior Q3 2026 estimate.","As of March 31, 2025, cash, cash equivalents and marketable securities were approximately $25.8 million.","Revised guidance based on existing and planned activities; no other material changes disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0000320017-25-000039","json":"https://secwatch.observer/filing/0000320017-25-000039.json","markdown":"https://secwatch.observer/filing/0000320017-25-000039.md","text":"https://secwatch.observer/filing/0000320017-25-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/320017/000032001725000039/0000320017-25-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/320017/000032001725000039/clbs-20250617.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T05:22:05.035991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}